News Alkermes closing in on Biogen with MS rival ALKS 8700 may have fewer side effects than Tecfidera.
News Apitope to develop MS drug, Merck KGaA tie-up ends Anglo-Belgian biotech will continue clinical development.
News Biogen takes on Tecfidera adherence issues Company hopes to coach patients with stomach side-effects.
News Novartis drug effective in advanced MS Siponimod slowed disability progression in secondary progressive multiple sclerosis
News Scangos to leave Biogen at a crossroads Company has grown, but direction towards next stage is unclear
News CDC panel votes to scrap hepatitis B birth dose advice CDC advisers vote to overturn decades of US policy and abandon endorsement of universal hepatitis B vaccination for newborns in the US.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
